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Introduction: Pregnancy is known to cause red blood cell (RBC) 
alloimmunisation which may lead to the production of harmful alloantibodies and a 
subsequent potential for causing haemolytic disease of fetus and newborn (HDFN). 
However, RBC alloantibodies are significantly different between different populations 
and ethnic groups.  
 
Objectives: The aim of this study is to determine the prevalence of RBC 
alloantibodies among Malay pregnant women and their association with HDFN. 
 
Patients and Methods: Clinical and serological data of 5163 Malay pregnant 
women who attended labour room, Hospital Universiti Sains Malaysia from January to 
December 2009 were collected and analyzed prospectively. The blood samples were 
subjected to the standard immunohaematological procedure for red cell antibody 
screening and identification. The newborns of women with positive antibody screening 
were monitored for the evidence of HDFN.  
 
Results: Fifty one (0.99%) pregnant women were found to have irregular RBC 
alloantibodies and when the specificities were further characterized, 30 (0.58%) women 
were found to possess clinically significant alloantibodies. Most of the clinically 
significant alloantibodies belonged to Rhesus (Rh) system (55.8%) where anti-E (33.3%) 
was the most common antibody identified, followed by anti-D (10.0%). There was 
significant association between RBC alloimmunisation in Malay pregnant women and 
RhD blood group, history of abortion, preterm labour, APH, IUD and history of blood 
transfusion. Fourteen (0.27%) neonates were clinically diagnosed as HDFN. Anti-D, anti-
c and anti-K were identified to cause moderate to severe HDFN.  
 
Conclusion: The prevalence of RBC alloantibody in Malay pregnant women is 
low (<1%), which is similar to other published studies. There were differences in the 
distribution of alloantibody specificity, however the antibodies toward Rh antigen are still 
the commonest clinically significant alloantibody identified. Considering the low 
prevalence of clinically significant alloantibodies and HDFN, the value of current routine 
antenatal RBC antibody screening practice in most Western countries becomes 
questionable and may not be directly applicable to Malaysian community without some 
modification. It is recommended that the antibody screening test should be restricted to 
women who are RhD negative, or with past history of HDFN especially due to anti-c and 
anti-K.  
 
 
Prof. Madya Dr Rapiaah Bt Mustaffa: Supervisor 
Prof. Madya Dr. Shah Reza Johan Noor: Co-Supervisor 
Dr Noor Haslina Mohd Noor: Co-Supervisor 
 
: 
 
RED BLOOD CELL ALLOANTIBODIES DETECTION IN MALAY PREGNANT 
WOMEN AND HAEMOLYTIC DISEASE OF FETUS AND NEWBORN 
 
 
By: 
DR MOHD NAZRI HASSAN 
M.D (UKM) 
 
 
 
Dissertation Submitted In Partial Fulfillment Of The Requirements For The Degree Of 
Master Of Pathology (Haematology) 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
MAY 2011 
  ii 
ACKNOWLEDGEMENT 
 
It was a very satisfactory for me to be able to complete this dissertation. Firstly, 1 would 
like to express my thankfulness and praises to Allah S.W.T for giving me the strength and 
ability to complete this dissertation. In the process of completing this project, I am 
indebted to many people of their assistance. 
 
My deepest appreciation goes to Associate Professor Dr Rapiaah Mustaffa, my supervisor 
and lecturer from Haematology Department, HUSM for the advice and ideas and her 
continuous supervision, support and guidance in this study. 
 
I am also very grateful to my co-supervisor, Associate Professor Dr Shah Reza Johan 
Noor, lecturer from Obstetric and Gynaecology Department for the advices and ideas and 
also for allowing me to carry out sample collection in labour room, HUSM. I am also very 
thankful to my second co-supervisor, Dr Noor Haslina Mohd Noor, lecturer from 
Haematology Department HUSM for the advice and ideas. 
 
Many thanks to labour room’s HUSM staff nurse for helping me to carry out sample 
collection and to all staffs in the blood bank and haematological laboratory for their 
invaluable contribution. Finally, I would like to thank my family especially my wife, Pn 
Marwani Athirah Md Zain for her understanding, support and encouragement throughout 
this study. 
 
  iii 
TABLE OF CONTENTS         
Contents Page 
Acknowledgement ………………………………………………………… ii 
Table of contents  ………………………………………………………….. iii 
List of tables ……………………………………………………………….. vi 
List of figures ……………………………………………………………… vii 
List of abbreviations ……………………………………………………… viii 
Abstrak (in Malay language) …………………………………………….. x 
Abstract (in English) ……………………………………………………… xii 
CHAPTER 1:  INTRODUCTION  
1.1  General introduction …………………………………………… 2 
1.2  Red blood cell alloantibody ……………………………………. 4 
CHAPTER 2:  LITERATURE REVIEW  
2.1  Blood grouping and antibody testing in pregnancy ……………. 9 
2.1.1  Introduction …………………………………………….. 9 
2.1.2 Objectives of prenatal testing…………………………… 10 
2.1.3 Testing protocol ………………………………………... 10 
2.2  Red blood cell alloimmunisation in pregnancy ………………... 14 
2.2.1  Introduction …………………………………………….. 14 
2.2.2 RhD immunisation in pregnancy ………………………. 16 
2.2.3 Non-RhD immunisation in pregnancy …………………. 18 
2.2.4 Risk factors …………………………………………….. 20 
  
  iv 
2.3  Red cell serology techniques …………………………………… 22 
2.3.1 Introduction …………………………………………….. 22 
2.3.2 Indirect antiglobulin test ……………………………….. 22 
2.3.3  Microcolumn gel agglutination system ………………… 23 
2.4  Haemolytic disease of fetus and newborn ……………………… 26 
2.4.1 Introduction …………………………………………….. 26 
2.4.2 Prevalence of HDFN due to RhD antibody ……………. 28 
2.4.3 Prevalence of HDFN due to non-RhD antibody ……….. 29 
2.4.4 Prevention of RBC alloimmunisation and HDFN ……... 34 
2.4.5 Treatment and management of HDFN …………………. 38 
CHAPTER 3:  OBJECTIVES  
3.1  General objective ………………………………………………. 41 
3.2  Specific objectives ……………………………………………... 41 
CHAPTER 4:  RESEARCH METHODOLOGY  
4.1  Study design ……………………………………………………. 43 
4.2  Materials ………………………………………………………... 44 
4.3  Criteria for diagnosis of HDFN ………………………………... 48 
4.4  Laboratory methods ……………………………………………. 48 
4.4.1 Procedure for preparing cell suspension ……………….. 49 
4.4.2 Procedure for ABO and RhD grouping ………………… 50 
4.4.3 Procedure for antibody screening ……………………… 50 
4.4.4 Procedure for antibody identification ………………….. 51 
4.4.5 Procedure for DCT ……………………………………... 51 
  v 
4.4.6 Test reaction ……………………………………………. 51 
4.4.7 Procedure for FBP ……………………………………… 53 
4.4.8 Procedure for measurement of serum bilirubin ………… 54 
4.5  Statistical analysis ……………………………………………… 54 
CHAPTER 5:  RESULTS  
5.1  Demographic data ……………………………………………… 56 
5.2  Prevalence of RBC alloantibodies in Malay pregnant women … 59 
5.3  The characteristic of alloimmunised Malay pregnant women …. 64 
5.4  Risk factors and their association with RBC alloimmunisation 
in Malay pregnant women ………………………………………  
  
67 
5.5  Neonate outcome ……………………………………………….. 70 
CHAPTER 6:  DISCUSSION  
6.1  Prevalence of irregular RBC alloantibodies …………………….  74 
6.2  Clinically significant RBC alloantibodies and infant outcome … 77 
6.2.1 Rhesus antibodies ………………………………………. 78 
6.2.2 Non-Rhesus antibodies ………………………………… 85 
6.3  Risk factors of RBC alloimmunisation in pregnancy …………..  88 
CHAPTER 7:  LIMITATIONS ……………………………………….. 91 
CHAPTER 8:  CONCLUSION ………………………………………... 93 
REFERENCES ………………………………………………………………... 96 
APPENDICES  
 
 
 
 
  vi 
LIST OF TABLES 
 
Table 1.1 Type of clinically significant blood group antibodies 
Table 2.1  Non-RhD antibodies associated with HDFN 
Table 2.2  Recommendation for antenatal and postnatal test and the prevention of RhD 
immunisation 
Table 2.3  Events following which anti-D Ig must be given to all RhD negative women  
with no anti-D and/or with antibodies other than anti-D 
Table 5.1  Characteristics of Malay pregnant women who attended HUSM labour 
room from January to December 2009 
Table 5.2  Results of RBC alloantibodies identification in Malay pregnant women 
Table 5.3  Spectrum of irregular RBC alloantibody detected in 51 alloimmunised 
Malay pregnant women 
Table 5.4  Frequency of 63 irregular RBC alloantibodies according to the antigen 
systems 
Table 5.5  Type of clinically significant irregular antibody identified and the neonate 
outcome  
Table 5.6  Factors associated with RBC alloimmunisation in Malay pregnant women 
Table 5.7  Clinical data of 14 women who possessed clinically significant alloantibody 
and their neonate details 
 
 
 
 
  vii 
LIST OF FIGURES 
 
Figure 2.1 Algorithm for blood group and antibody testing in pregnancy 
Figure 2.2  Principle of gel column agglutination system 
Figure 4.1  Flow chart of the study  
Figure 4.2  Grading of reaction with microcolumn gel system 
Figure 5.1  Characteristic of pregnant women who attended HUSM labour room from 
2009 to 2010 by blood group 
Figure 5.2  Distribution of alloimmunised pregnant women by gravidity group 
Figure 5.3  Distribution of alloimmunised pregnant women by age group  
Figure 5.4  Distribution of alloimmunised pregnant women by ABO blood group 
Figure 5.5  Distribution of alloimmunised pregnant women by RhD group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  viii 
ABBREVIATIONS 
 
Anti  antibody 
APH  antepartum haemorrhage 
BCSH  British Committee for Standards in Haematology 
DCT  direct Coombs test 
EDTA  ethylenediamine tetra-acetic acid 
ET  exchange transfusion 
FBP  full blood picture 
FMH  fetomaternal haemorrhage 
Fy  Duffy 
Hb  haemoglobin 
HDFN  haemolytic disease of fetal and newborn 
HTR  haemolytic transfusion reaction 
HUSM  Hospital Universiti Sains Malaysia 
IAT  indirect antiglobulin test 
Ig  immunoglobulin 
IgG  immunoglobulin G 
IgM  immunoglobulin M 
IM  intramuscular 
IU  international unit 
IV  intravenous 
IVIg  intravenous immunoglobulin 
  ix 
IUD  intrauterine death 
Jk  Kidd 
K  Kell 
LSCS  lower segment caesarean section 
Le  Lewis 
LISS  low ionic strength saline 
Lu  Lutheran 
PDN   National Blood Centre of Malaysia 
PC  packed cells 
RBC  red blood cell 
rEPO  recombinant erythropoietin  
Rh  Rhesus 
RhD  Rhesus D 
 
 
 
 
 
 
 
 
 
 
 
  x 
ABSTRAK 
 
PENGESANAN ALLOANTIBODI TERHADAP SEL DARAH MERAH DI 
KALANGAN WANITA MELAYU HAMIL DAN PENYAKIT HEMOLISIS FETUS 
DAN BAYI BARU LAHIR 
 
Proses penghamilan merupakan salah satu penyebab alloimunisasi sel darah merah di mana 
ia boleh menjurus kepada pembentukan alloantibodi dan seterusnya berpotensi untuk 
menyebabkan penyakit hemolisis fetus dan bayi baru lahir. Walaubagaimanapun, 
alloantibodi terhadap sel darah merah adalah berlainan mengikut populasi dan kaum. 
Tujuan kajian ini adalah untuk mengenalpasti prevalens alloantibodi terhadap sel darah 
merah di kalangan wanita Melayu yang hamil dan hubungannya dengan penyakit hemolisis 
fetus dan bayi baru lahir. 
 
Data klinikal dan serologi daripada 5163 orang wanita Melayu hamil yang datang ke 
dewan bersalin, Hospital Universiti Sains Malaysia dari bulan Januari hingga Disember 
2009 dikumpul dan dianalisa secara prospektif. Sampel darah dianalisa mengikut prosedur 
tabung darah yang standard untuk ujian saringan dan penentuan antibodi. Bayi kepada 
wanita yang mempunyai saringan antibodi yang positif diawasi untuk penyakit hemolisis 
fetus dan bayi baru lahir.  
 
Lima puluh satu (0.99%) orang wanita mengandung didapati mempunyai alloantibodi 
terhadap sel darah merah dan apabila spesifisiti mereka dikenalpasti dengan lebih lanjut, 
  xi 
30 (0.58%) orang didapati mempunyai alloantibodi yang signifikan secara klinikal. 
Kebanyakan daripada alloantibodi yang signifikan secara klinikal adalah dari sistem 
Rhesus (55.8%) di mana anti-E (33.3%) merupakan antibodi yang paling kerap 
dikenalpasti, diikuti oleh anti-D (10.0%).  Terdapat hubungan yang signifikan di antara 
alloimunisasi sel darah merah wanita Melayu hamil dengan kumpulan darah RhD, sejarah 
keguguran, kelahiran pramatang, pendarahan antepartum, kematian di dalam rahim dan 
sejarah transfusi darah. Empat belas (0.27%) orang bayi didapati mempunyai penyakit 
hemolisis fetus dan bayi baru lahir secara klinikal. Anti-D, anti-c dan anti-K dikenalpasti 
menyebabkan penyakit hemolisis fetus dan bayi baru lahir yang sederhana dan teruk.  
 
Kesimpulannya, prevalens alloantibodi terhadap sel darah merah di kalangan wanita 
Melayu hamil adalah rendah (<1%), seperti yang telah dilaporkan oleh kajian-kajian 
terdahulu. Walaupun terdapat kelainan pada taburan spesifisiti antibodi, antibodi terhadap 
kumpulan antigen Rhesus adalah yang paling kerap dikenalpasti. Memandangkan 
rendahnya prevalens alloantibodi yang signifikan secara klinikal dan penyakit hemolisis 
fetus dan bayi baru lahir, nilai saringan antibodi terhadap sel darah merah semasa hamil 
yang diamalkan di kebanyakan negara barat kemungkinannya tidak begitu sesuai 
dijalankan di Malaysia sekiranya tidak diubahsuai. Saringan antibodi dicadangkan hanya 
kepada wanita yang RhD negatif, atau mempunyai sejarah penyakit hemolisis fetus dan 
bayi baru lahir terutamanya disebabkan oleh anti-c dan anti-K.  
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ABSTRACT 
 
RED BLOOD CELL ALLOANTIBODIES DETECTION IN MALAY PREGNANT 
WOMEN AND HAEMOLYTIC DISEASE OF FETUS AND NEWBORN 
 
Pregnancy is known to cause red blood cell (RBC) alloimmunisation which may lead to 
the production of harmful alloantibodies and a subsequent potential for causing haemolytic 
disease of fetus and newborn (HDFN). However, RBC alloantibodies are significantly 
different between different populations and ethnic groups. The aim of this study is to 
determine the prevalence of RBC alloantibodies among Malay pregnant women and their 
association with HDFN. 
 
Clinical and serological data of 5163 Malay pregnant women who attended labour room, 
Hospital Universiti Sains Malaysia from January to December 2009 were collected and 
analyzed prospectively. The blood samples were subjected to the standard 
immunohaematological procedure for red cell antibody screening and identification. The 
newborns of women with positive antibody screening were monitored for the evidence of 
HDFN.  
 
Fifty one (0.99%) pregnant women were found to have irregular RBC alloantibodies and 
when the specificities were further characterized, 30 (0.58%) women were found to 
possess clinically significant alloantibodies. Most of the clinically significant 
alloantibodies belonged to Rhesus (Rh) system (55.8%) where anti-E (33.3%) was the 
  xiii 
most common antibody identified, followed by anti-D (10.0%). There was significant 
association between RBC alloimmunisation in Malay pregnant women and RhD blood 
group, history of abortion, preterm labour, APH, IUD and history of blood transfusion. 
Fourteen (0.27%) neonates were clinically diagnosed as HDFN. Anti-D, anti-c and anti-K 
were identified to cause moderate to severe HDFN.  
 
In conclusion, prevalence of RBC alloantibody in Malay pregnant women is low (<1%), 
which is similar to other published studies. There were differences in the distribution of 
alloantibody specificity, however the antibodies toward Rh antigen are still the commonest 
clinically significant alloantibody identified. Considering the low prevalence of clinically 
significant alloantibodies and HDFN, the value of current routine antenatal RBC antibody 
screening practice in most Western countries becomes questionable and may not be 
directly applicable to Malaysian community without some modification. It is 
recommended that the antibody screening test should be restricted to women who are RhD 
negative, or with past history of HDFN especially due to anti-c and anti-K.  
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Chapter 1 
 
 
INTRODUCTION 
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1.0 INTRODUCTION 
 
1.1 GENERAL INTRODUCTION 
 
Red blood cell (RBC) alloimmunisation may develop during pregnancy or from previous 
blood transfusion. During pregnancy this maternal RBC alloimmunisation may lead to 
production of harmful antibodies that result in haemolytic disease of fetus and newborn 
(HDFN). The destruction of the fetus and newborn RBC are most commonly due to ABO 
incompatibility or irregular maternal RBC alloantibodies which are clinically significant.  
 
The International Society of Blood Transfusion recognized 302 blood group antigens, most 
of which belong to 1 of 29 genetically discrete blood group system (Poole and Daniels, 
2007). Antibodies toward many of these RBC antigens have the potential to be clinically 
significant in which they can either facilitate accelerated destruction of RBC carrying the 
corresponding antigen manifest as a haemolytic transfusion reaction (HTR) and to be 
transferred across the placenta and cause HDFN.  
 
More than 50 different RBC antigens have been reported to be associated with HDFN 
(Moise, 2008).  However these RBC antigens are significantly different between different 
populations and different ethnic groups. There is a recognized existence of difference in 
RBC alloantibodies in different ethnic groups because of racial difference of blood group 
distribution. Consequently, the alloantibodies contributing to HDFN are also different.  
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The prevalence of irregular and clinically significant RBC alloantibodies had been studied 
in the Western and Chinese pregnant women in Hong Kong. The incidence of irregular 
antibodies was reported to be about 1-2% in Western pregnant women (Weinstein, 1982). 
Previous study done in Hong Kong reported the prevalence of irregular and clinically 
significant antibodies in the Chinese pregnant women was 0.64% and 0.27% respectively 
(Lee et al., 2003). Other study by Wong et al. (1997) reported the similar finding, a 
prevalence of irregular and clinically significant alloantibodies of 0.85% and 0.20% 
respectively. There is so far no information about the prevalence of maternal irregular 
antibodies in the Malaysian population especially in Malays and very little information 
about HDFN due to maternal RBC alloantibodies. 
 
Guidelines for blood grouping and RBC antibody testing and the prevention and 
management of RBC alloantibodies during pregnancy are well established in Caucasian 
populations (BCSH, 1996a). In Western, routine prenatal and perinatal screening for 
irregular antibodies is mandatory. Applicability of this guideline to Malaysian population 
is unknown as a result of insufficient data on the prevalence of maternal irregular RBC 
alloantibodies and their outcomes. 
 
We hope that this study will contribute to a better comprehension of the problem and will 
help to develop our own guideline for the prevention and management of RBC 
alloantibodies during pregnancy and subsequently can predict and treat HDFN very 
efficiently to reduce neonatal morbidity and mortality. 
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1.2 Red blood cell alloantibody 
 
RBC alloantibodies are the antibodies that develops in a people who have been exposed to 
foreign RBC alloantigen either from blood transfusion or fetomaternal haemorrhage 
(FMH) during pregnancy and delivery. Antibody detection and identification are very 
important in transfusion practice and provide information which aids in the selection of 
suitable blood for transfusion (Poole and Daniels, 2007) and in prediction of occurrence 
and severity of HDFN.  
 
Irregular RBC alloantibodies are the antibodies that against RBC antigens other than ABO 
group which usually develop in response to exposure to foreign RBC antigens, but may 
occur naturally from exposure to bacteria or viruses. The development of these antibodies 
are more common in reproductive age women than men because sensitisation is often due 
to pregnancy related events, such as fetomaternal transfusion and blood transfusion for 
postpartum haemorrhage (Barss and Moise, 2008). Irregular alloantibodies can be either 
clinically significant or insignificant. With few exceptions, irregular antibodies which are 
potentially clinically significant are only those which are reactive in the indirect 
antiglobulin test (IAT) and performed strictly at 37oC (Chapman et al., 1996). 
 
A clinically significant alloantibody is defined as an antibody that is capable to accelerate 
destruction of RBC bearing the relevant antigen. Anti-A, anti-B and anti-A,B should 
always be regarded as the clinically significant antibody as they are known to cause severe 
HTR as well as HDFN (Chapman et al., 1996). The examples of clinically significant 
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alloantibodies are shown in Table 1.1. The clinically significant alloantibodies frequently 
are associated with HDFN, HTR or with a notable decrease in the survival of transfused 
red cells. The degree of clinical significance varies among antibodies with the same 
specificities, in which some cause destruction of incompatible RBC within hours or even 
minutes; whereas others cause a decrease in the RBC survival, and still others cause no 
discernible shortened RBC survival (Roback et al., 2008, Chapman et al., 1996). In view 
of that, distinguishing between potentially clinically significant and non-clinically 
significant antibodies is important in alloimmunised women to predict the severity of 
HDFN and in patients with alloantibodies who require blood transfusion when compatible 
donors are not available. 
 
The clinical significance of blood group system depends mainly on the frequency with 
which alloantibodies of the system occur and the characteristic of the alloantibodies, 
namely their destructive capacity, antibody strength, immunoglobulin (Ig) class, IgG 
subclass, mode of reactivity, thermal range and ability to fix complement. These 
characteristics determine the clinical significance of the antibody either to cause RBC 
destruction which manifest as a HTR and to be transferred across the placenta and cause 
HDFN (Klein and Anstee, 2006).  
 
Other factors that can also influence the pathogenicity of an antibody are the quantity and 
distribution of target antigen on RBC membrane, the quantity of IgG and/or complement 
bound to the RBC and the presence of target antigen in tissues and/or body fluids, and the 
most important of these is thermal amplitude since if the antibody does not react at 37oC, it 
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should cause no significant in vivo RBC destruction and no immediate clinical effects due 
to an immune reaction (Poole and Daniels, 2007, Hoffbrand et al., 2005). 
 
 
Table 1.1: Type of clinically significant blood group antibodies  
 
System No. of 
antigens 
HTR HDFN 
    
ABO  4 Anti-A, -B, -A,B cause severe and 
often fatal HTR. 
Rare and usually mild 
Rhesus (Rh)  49 Cause severe I and D HTR. Cause severe HDFN 
MNS  
 
46 
 
Rare examples of anti-M and -N 
active at 37°C cause I and D HTR. 
Anti-S, -s, -U, and some other 
antibodies cause I and D HTR. 
Anti-S, s, -U, and some 
other antibodies cause 
severe HDFN. 
Anti-M, rarely. 
Kell (K) 28 Cause severe I and D HTR Cause severe HDFN 
Duffy (Fy) 
 
6 
 
Anti-Fya, -Fyb, and -Fy3 cause I and 
D HTR; anti-Fy5, D HTR. 
Anti-Fya and -Fyb cause 
HDFN. 
Kidd (Jk) 
 
3 
 
Common cause of D HTRs. Anti-Jka 
and -Jk3 also cause I HTR. 
Not usually 
Lutheran  (Lu) 19 Anti-Lua and -Lub have caused mild D 
HTR. 
No 
Lewis (Le) 6 Not generally considered clinically 
significant 
No 
P1  1 
 
Only very rare examples active at 
37°C cause I and D HTR. 
No 
Diego  
 
21 
 
Anti-Dia and -Dib, no evidence. 
Anti-Wra has caused HTR. 
 
Anti-Dia, -Dib, -Wra, and -
Wrb, plus some others have 
caused severe HDFN 
Yt  2 Anti-Yta very rarely caused HTR. No 
Xg 2 No No 
Scianna  7 No No 
Dombrock  5 Anti-Doa and -Dob cause I and D 
HTRs. 
No 
 
Colton  
 
3 
 
Anti-Coa causes I and D HTR. 
Anti-Cob and -Co3 have caused mild 
HTRs. 
Anti-Coa has caused severe 
and anti-Co3 mild HDFN 
LW  3 No No  
Ch/Rg  9  No  No 
H  
 
1 Anti-H in Bombay phenotype can 
cause severe intavascular HTR. 
Anti-HI in para-Bombay not usually 
clinically significant. 
Anti-H in Bombay 
phenotype has potential to 
cause severe HDFN 
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“Table 1.1 Continued” 
 
System No. of 
antigens 
HTR HDFN 
    
Kx  
 
1 
 
Anti-Kx + -Km in McLeod syndrome 
has caused severe HTR.  
Antibodies only found in 
males 
Gerbich 8  No 
 
One example of anti-Ge3 
causing HDFN 
Cromer  15  No  No 
Knops + 
COST  
9 + 2 
1 
No 
No 
No  
No 
Indian  4 One example of anti-Inb causing an 
HTR No 
Ok  1 Very rare and no HTR reported No 
JMH  
 
5 
 
One example of anti-JMH 
reported to have caused IHTR No 
I  
 
1 Anti-I in adult i phenotype has caused 
increased destruction of I+ red cells. 
No 
 
GLOB + 
PP1Pk and 
LKE  
1 + 2 Anti-P and -PP1Pk cause intravascular 
HTR. 
LKE not clinically significant. 
No, but high rate of 
spontaneous abortion with 
anti-P and -PP1Pk 
GIL  1 No No 
Er  2 No No 
Vel  2 
 
Anti-Vel causes severe intravascular 
HTR. 
Little is known about anti-ABTI. 
Generally no, but 1 case 
reported 
LFAs 
(700 series) 
19 Little evidence as compatible 
red cells readily available 
 
Anti-JFV, -Kg, -JONES, -
HJK and -REIT have caused 
HDFN 
HFAs  
(901 series) 
9 Anti-Lan: 1 example caused IHTR. 
Anti-Ata: reported to have caused 
HTR 
Anti-Jra: 1 example caused I HTR. 
Anti-AnWj: severe HTR 
Anti-PEL, -MAM: very rare, but 
could be clinically significant 
Anti-Emm, -Sda: no 
Anti-Ata: 1 report of mild 
HDFN  
Anti-MAM: caused severe 
HDFN  
Anti-Lan, -Jra, -Emm, -
AnWj, anti-PEL, -Sda: no 
 
 
 
    
(Adapted from Poole and Daniels, 2007) 
 
I = immediate  D=delayed   
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2.0 LITERATURE REVIEW 
 
2.1 Blood grouping and antibody testing in pregnancy 
 
2.1.1  Introduction 
 
Following British Committee for Standards in Haematology (BCSH) guideline for blood 
grouping and antibody testing during pregnancy, it was mandatory for every pregnant 
woman in Western countries to do routine prenatal screening for irregular RBC 
alloantibodies (BCSH, 1996a). ABO and RhD grouping as well as antibody screening on 
the sera of pregnant women were routinely performed for the protection of the mother and 
identification of HDFN (Mitchell et al., 1996). 
 
Although antenatal antibody screening was mandatory in Western population, Wong et al. 
(1997) reported that this practice might not be necessary in the Chinese population except 
for those who were RhD negative or who had history of HDFN.  Wu et al. (2003) also 
reported similar finding that routine prenatal screening for irregular antibodies was not 
rational in the Chinese population in Taiwan because of very low prevalence of HDFN 
caused by maternal irregular RBC alloantibodies. (Wu et al., 2003).  
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2.1.2 Objectives of prenatal testing 
 
The objectives of prenatal and perinatal testing are essentially threefold: first is to identify 
RhD negative women who need anti-D Ig prophylaxis; second to identify women with 
potentially significant alloantibodies to RBC antigens who are at risk of HDFN; and third 
to assist in the diagnosis and management of HDFN, both during pregnancy and at delivery 
(BCSH, 1996a, Judd, 2001).  
 
An additional benefit of the prenatal antibody screening program is the detection of RBC 
antibodies, relevant in case of transfusion to the mother and it can save time, needed for the 
identification of antibody specificities (Koelewijn et al., 2008). Without antibody 
screening, two-thirds of the RBC alloantibodies will not be known at pre-transfusion 
laboratory testing (BCSH, 1996a).  
 
2.1.3 Testing protocol 
 
Prenatal immunohaematologic care of pregnant women including ABO, RhD groups and 
antibody screen should be performed in all pregnant women at booking (usually around 16 
weeks’ gestation). All women should have the testing repeated once more at about 28 
weeks to confirm the RhD group and to detect the presence of irregular antibodies (BCSH, 
1996a).  
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When RBC antibody screening is positive, it is necessary to determine specificity of the 
antibody, its clinical importance, and the ability to cross the placenta and cause HDFN.  
Neither the specificity nor the level of maternal RBC antibodies can precisely predict the 
outcome of infant (BCSH, 1996a).  
 
If clinically significant antibodies are detected, more frequent testing will be required. If 
the mother is RhD negative with no anti-D by 28 weeks, routine antenatal prophylaxis 
should be given at 28 and 34 weeks of gestation. Following delivery, all RhD negative 
women who are unsensitised for RhD should be given prophylactic anti-D Ig if the infant 
is RhD positive (Hoffbrand et al., 2005).  
 
For the women with anti-D, they should be monitored for the anti-D level, however 
titration of anti-D does not closely correlate with the occurrences of HDFN (Judd, 2001). 
Although titration of anti-D does not closely correlate with the occurrences of HDFN, new 
reference reports that there is a correlation between the titre and the severity of the HDFN 
(Hoffbrand et al., 2005).  The anti-D quantification (IU/ml) using the national anti-D 
standard is more reproducible and correlates more closely with the likelihood of HDFN 
(BCSH, 1996a). Blood group and antibody testing in pregnancy that had been suggested by 
BCSH are shown in Figure 2.1.  
 
First trimester antibody screening enables timely treatment of HDFN caused by antibodies 
other than anti-D, however, with a sensitivity of only 75%. A second screening at 30th 
week of gestation, will enhance the screening program (Koelewijn et al., 2008).  However, 
Judd (2001) reported that in most cases, RhD positive patients need be screened for 
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antibodies only once during pregnancy, at the initial visit and routine repeated testing for 
unexpected antibodies in the third trimester or at delivery will rarely yield useful 
information. Rothenberg et al. (1999) also reported that a repeat third-trimester antibody 
screen for RhD positive patients was clinically and economically unjustified and 
eliminating this laboratory test from clinical practice would not adversely affect pregnancy 
outcomes and would decrease the costs of prenatal care. 
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Figure 2.1: Algorithm for blood group and antibody testing in pregnancy (adapted from 
Hoffbrand et al., 2005) 
 
All pregnant women: 
Booking visit 10–16 weeks: send sample to blood bank. 
Testing will be performed for ABO, RhD blood groups + antibody screen. 
• Clinical information regarding the week of pregnancy/EDD at time of booking sample must   
   be included on request form 
• Clinical information regarding previous pregnancies/transfusions must be included on  
   request if  known. 
• Use of consultant code assists in identifying a sample as antenatal  
• Objectives: identify pregnancies at risk of fetal/neonatal HDFN. 
                   : identify RhD-negative women who need anti-D prophylaxis 
                   : provide compatible blood swiftly in obstetric emergencies 
All pregnant women 28 weeks: 
• Recheck RhD group and antibody testing 
RhD negative women at booking visit must have blood sample taken before giving injection 
of 28 weeks anti-D.prophylaxis (> 500 iu) (passive anti-D can be detected by IAT within 
minutes of the injection being given) 
Anti-D, anti-c,  
K-related antibodies Other antibodies No antibodies 
Monitor level monthly 
No other IAT 
reacting antibodies 
 
Anti-D, anti-c,  
K-related antibodies 
Other IAT reacting 
antibodies 
If significantly high 
refer to fetal 
medicine unit 
If RhD negative: 34-
week dose (> 500 iu) 
anti-D prophylaxis 
Monitor level 
every 2 weeks  
Monitor level and 
Inform obstetrician 
At delivery: test cord blood 
group if mother RhD negative At delivery perform direct Coombs test (DCT) 
Monitor baby for HDFN 
If baby is RhD positive, give mother an additional injection > 500 i.u. anti-D Ig within 72 h 
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2.2 RBC alloimmunisation in pregnancy  
 
2.2.1 Introduction 
 
Alloimmunisation is defined as the formation of antibodies when there is an exposition of 
the individual to non-self antigens, as it occurs, for example, in the transfusion of 
incompatible blood and pregnancies, in whom the fetus express in its sanguineous cells 
antigens exclusively of paternal origin (Baiochi and Nardozza, 2009). RBC 
alloimmunisation can cause variety of problems during long-term medical and transfusion 
management, with the main problem being the identification of appropriate antigen 
negative RBC for transfusion to avoid HTR.  
 
Despite the widespread use of both antenatal and postpartum anti-D Ig, RBC 
alloimmunisation in pregnancy continues to occur. It was mainly due to inadvertent 
omissions in administration as well as antenatal sensitisation prior to anti-D Ig given at 28 
weeks of gestation and additional factors which included the lack of immune globulins to 
other RBC antigens (Moise, 2005). The advent of the routine administration of antenatal 
and postpartum RhD Ig had resulted in a shift of cases of RBC alloimmunisation to other 
antibodies (Moise, 2000).  
 
The most frequent causes of RBC immunisation were transfusion and pregnancy since 
neither the transfused RBC nor the fetal RBC perfectly matched those of the recipient 
(Koelewijn et al., 2009b). Most of the alloantibodies were produced in response to 
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immunisation by antigen positive RBC, either cells of fetal origin following FMH mostly 
during previous pregnancy from a blood group antigen mismatched fetus or at parturition 
or donor RBC following transfusion (Poole and Daniels, 2007).  
 
In pregnancies in which the mother was alloimmunised, the role of transfusion service was 
to determine antibody specificity.  When potentially clinically significant antibodies were 
present, antibody levels should be monitor and the data obtained were used to determine if 
and when to monitor for HDFN (Judd, 2001). It is important to identify all RBC 
alloantibodies whether there is a risk of HDFN or not and to facilitate cross matching of 
maternal blood if an emergency transfusion is required at delivery.  
 
Whenever the maternal serum had been identified to contain an immune, IAT reactive 
RBC alloantibody, a direct Coombs test (DCT) should be done on the fetal sample. A 
positive DCT in itself is not diagnostic of HDFN. However if it is positive, the infant’s 
haemoglobin (Hb) and bilirubin levels should be checked to diagnose/exclude HDFN. 
Where the DCT is positive and the infant shows symptoms of HDFN, an RBC eluate may 
be helpful to confirm the RBC antibody specificity. In cases of suspected HDFN wherever 
possible the RBC from the cord should be tested for the corresponding antigens (BCSH, 
1996a). 
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2.2.2 RhD immunisation in pregnancy 
 
In the case of RhD immunisation, the common sequence is a prior pregnancy with an RhD 
positive fetus, which had induced FMH related immunisation and a subsequent pregnancy 
with another RhD positive fetus will triggers manifest disease. The  combined  strategy of 
giving anti-D Ig in high-risk conditions during pregnancy and delivery with routine 
postnatal administration as part of national prevention programs had substantially 
decreased RhD immunisation in all developed countries (Koelewijn et al., 2009a). RhD 
immunisation also decreased strongly because of the policy of matching RBC transfusion 
for RhD antigen (Koelewijn et al., 2009a). 
 
RhD immunisation can occur during a first pregnancy with no history of preceding 
abortion or transfusion may result when RhD incompatible fetal to maternal bleeding 
ensues early enough in the gestation to initiate a maternal immune response before 
parturition. The antepartum usage of anti-D Ig had potential prophylactic value in this 
situation (Scott et al., 1977). 
 
The factors influence the immune response to RhD positive cells mothers includes: 1. 
Concomitant ABO incompatibility offers the mother protection against immunisation 
presumably because leaked foetal RBC are promptly coated by circulating IgM and 
probably also by complement, and then removed from the circulation by the mononuclear 
phagocyte system, therefore is less likely to stimulate antibody production; 2. The 
likelihood of anti-D appearing in the maternal circulation depends on the size of 
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transplacental FMH where although the average FMH occurring at delivery is less than 1 
ml of whole blood, approximately less than 1% of RhD negative women bearing RhD 
positive fetus have detectable circulating anti-D in their sera; 3. The likelihood of anti-D 
appearing in the maternal circulation also depends on the Rh phenotype of the fetal blood 
where infants with R2r (cDE/cde) phenotype are more effective in sensitising their mothers 
to RhD than are infants of other phenotypes, since the R2 (cDE) phenotype expresses most 
D antigen; and 4. The pregnant mother’s immune responsiveness influences the immune 
response to RhD positive cells. Some women produce potent anti-D in a first pregnancy 
sufficient to cause severe HDFN but usually no first child of an RhD negative woman will 
be affected, unless the mother has been sensitised as a result of a prior miscarriage or 
abortion or, rarely, by a sensitising event earlier in the pregnancy (Kumar et al., 2009). 
 
Before the introduction of immunoprophylaxis, anti-D was found in approximately 1 in 
170 pregnant white women, both in England and in North America. With early detection 
and following the introduction of immunoprophylaxis with anti-D in the late 1960, the 
frequency is found has fallen progressively (Klein and Anstee, 2006).  
 
A relatively young age at first delivery, non-spontaneous delivery such as lower segment 
caesarean section (LSCS) or assisted vaginal delivery, post maturity of the previous 
pregnancy emerged and pregnancy-related RBC transfusion as independent risk factors 
that significantly contributed to the development of RhD antibodies (Koelewijn et al., 
2009a). Koelewijn et al. (2009a) also reported what the risk factors for RhD immunisation 
despite antenatal and postnatal anti-D prophylaxis and they found in at least half of the 
failures of anti-D Ig prophylaxis, was due to a condition related to increased FMH and/or 
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insufficient anti-D Ig levels given. Hence, RhD immunisation might be further reduced by 
strict compliance to guidelines concerning determination of FMH and accordingly adjusted 
RhD Ig prophylaxis, or by routine administration of extra anti-D Ig after a non-
spontaneous delivery and/or a complicated or prolonged third stage of labour. (Koelewijn 
et al., 2009a).  
Jovanovic-Srzentic et al. (2003) reported that according to published data, the incidence of 
clinically significant antibodies during pregnancy in Croatia was approximately 1% in 
which 64.8% were anti-D, 0.58% in Tyrol in which 54% were anti-D, 0.82% in Salzburg 
in which 48% were anti-D, and 0.24 percent in Sweden in which 32% were anti-D. 
(Jovanovic-Srzentic et al., 2003).  
Nordvall et al. (2009) also found that anti-D was the single most frequent and harmful 
antibody (46.6%) and the combinations with other antibody specificities were more 
harmful than single specificities. All three types of therapeutic intervention (intrauterine 
transfusion and simple transfusion) were significantly more frequent in women with anti-D 
plus an additional antibody than in women with anti-D as the sole antibody. The clinical 
importance of the antibody was closely paralleled to the anti-D level (Nordvall et al., 
2009).  
 
2.2.3 Non-RhD immunisation in pregnancy  
 
Non-RhD immunisation as a term, referring to the presence of all maternal RBC antibodies 
other than RhD antibodies and ABO antibodies that can theoretically cause HDFN. This 
includes all non-RhD RBC antibodies that can cross the placenta and are directed against 
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blood group antigens known to be expressed by the fetal RBC (Koelewijn et al., 2009b). 
Although the anti-D was, and still is the most common cause of severe HDFN, as RhD 
immunisation decreases due to RhD prevention program, other non-RhD alloantibodies 
have become more important as a cause. The antigens of the Rh system other than D which 
most common cause immunisation during pregnancy are C, c, E, and e (Tarsa and Kelly, 
2008). Previous study of RBC alloimmunisation among Saudi pregnant women also 
showed that importance of antigens other than RhD have been increased since the 
introduction of RhD prophylactic treatment where alloimmunisation to E, c and Kell (K) 
antigens can reach significant proportions of studied populations and can result in 
deleterious effects on fetus (Al-Ibrahim and Al-Saeed, 2008).  
 
In Netherlands, the prevalence of pregnancies with clinically relevant alloantibodies, other 
than anti-D, was 328 in 100,000. Anti-E was the most frequent alloantibody, followed by 
anti-K and anti-c. Combination of anti-c,-E were found in 14% of the index pregnancies, 
was the most frequent identified among alloantibodies of more than one specificity 
(Koelewijn et al., 2008).  
 
In Yugoslavia, the incidence of potentially clinically significant alloantibodies was 2.4%. 
Majority of those antibodies were belonged to the Rh system, followed by anti-M, -Fya, -S, 
-Jka, and -Jkb and among antibodies of no clinical significance, the most frequent were anti- 
H, -Lea, and -P1 (Jovanovic-Srzentic et al., 2003). Lewis (Le) antibodies are found more 
commonly in women in the reproductive period, a fact possibly related to the weakening of 
Le antigen on RBC in pregnancy (Klein and Anstee, 2006).  
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Alloimmunisation to K as a result pregnancy are relatively common, found in about 1 in 
1000 pregnant women, but assuming that K is 10 times less immunogenic than D, it can be 
shown that incidence of HDFN due to anti-K in second pregnancies would be expected to 
be only about 1 in 3500 (Klein and Anstee, 2006).  
 
Anti-M Antibodies specificity were detected in 10% of Swedish pregnant women with a 
positive antibody screen (Wikman et al., 2007). Lutheran (Lu) system antibodies are very 
rare and can occur in the absence of RBC stimulation. However, they are poorly developed 
at birth and have not been reported as a cause of HDFN (Al-Ibrahim and Al-Saeed, 2008). 
 
2.2.4 Risk factors  
 
Risk factors underlying RBC antigen immunisation in pregnancy were divided into general 
and pregnancy related risk factors. The age, history of RBC transfusion, history of platelet 
transfusion, parity, gravidity, ethnicity and variables related to increased risk of blood 
transfusion were listed as general risk factors whereas pregnancy related risk factors were 
all factors possibly related to increased FMH, such as miscarriage, termination of 
pregnancy, blood loss, trauma, invasive diagnostics in-utero, external version, twin 
pregnancy, postmaturity, LSCS, instrumental delivery and surgical removal of the placenta 
(Koelewijn et al., 2009b).  
 
Koelewijn et al. (2009b) reported that RBC transfusion was by far the most important 
independent risk factor for non-RhD immunisation in pregnancy, followed by parity, major 
surgery and haematological disease. Pregnancy-related risk factors are a prior male child 
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and LSCS. This approach will be equally sensitive in detecting severe HDFN compared 
with the present RBC antibody screening program without preselection. (Koelewijn et al., 
2009b). 
Sebring and Polensky (1990) also found that the potentially sensitising events in pregnancy 
can result from pathological conditions such as antepartum haemorrhage (APH), ectopic 
pregnancy, abdominal trauma, intrauterine death (IUD), miscarriage and termination of 
pregnancy and from invasive obstetrical procedures such as  amniocentesis, cordocentesis, 
chorionic villus sampling, other in-utero therapeutic intervention/surgery (e.g. intrauterine 
transfusion, shunting), manual removal of the placenta and external cephalic version. 
(Sebring and Polesky, 1990).  
Alloimmunisation depends on genetic and acquired patient-related factors, dose and route 
of administration, and the antigen immunogenicity, but exact kinetics are still unknown. 
The different blood group antigens will differ in their potency to induce an antibody 
response (immunogenicity), listed in order of decreasing immunogenicity: D > K > c > E > 
Fy > Jk (Schonewille et al., 2006). 
 
Pregnancies constitute a smaller stimulus compared to transfusion. There are two reasons, 
first, the number of foreign RBC antigen is limited to those possessed by the father of the 
fetus and second, in many pregnancies the amount of RBC transferred from fetus to mother 
is too small to stimulate a primary sensitisation (Klein and Anstee, 2006). The average 
volume of fetal blood in the maternal circulation following delivery is less than 1 ml in 
majority of women. Intrapartum FMH of more than 30 ml may occur in up to 1% of 
pregnancies (Sebring and Polesky, 1990, Hoffbrand et al., 2005).  
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Asymptomatic trans-placental passage of fetal RBC occurs in 75% of pregnant women at 
some time during pregnancy or during labour and delivery. The incidence of fetomaternal 
transfusion increases with advancing gestation: from 3% in the first trimester, 12% in the 
second trimester, 45% in the third trimester, to 64% at the time of delivery (Bowman et al., 
1986). Historically, the fetal effect of maternal RBC alloimmunisation was undetectable 
until after the birth of an affected infant. 
 
2.3 Red cell serology techniques 
 
2.3.1 Introduction 
 
The ability to detect and identify blood group antigens and antibodies has contributed 
enormously to current safe supportive blood transfusion practice and to the appropriate 
management of pregnancies at risk for HDFN (Reid et al., 2000). In immunohaematology 
laboratory, RBC antigen antibody are usually detected by agglutination tests, either in 
saline or macromolecular media, unmodified or with or without enzyme treated RBC and 
with or without use of low ionic media.   
 
2.3.2 Indirect antiglobulin test  
 
Indirect antiglobulin test is used to detect RBC antibodies in the serum (Daniels and 
Bromilow, 2007). The IAT using RBC suspended in low ionic strength saline (LISS) is 
considered to be the most suitable for detection of clinically significant antibodies. This is 
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because of its speed, sensitivity and specificity. Liquid-phase tube, microplate and 
microcolumn gel agglutination antiglobulin methods have all been shown reliable for 
antibody detection (BCSH, 1996b). Since IAT methods can detect almost all clinically 
significant antibodies, it is acceptable to use an IAT for pre-transfusion antibody screening 
without any additional screening technique.  
 
Additional techniques, such as enzyme and low temperature technique may be used, 
particularly when antibody weakly reactive by antiglobulin, or a mixture of antibodies is 
present.  However, there is no need for enzyme tests in prenatal testing because enzyme 
tests are not reliable in the prediction of HDFN (Hundric-Haspl et al., 1999). 
 
BCSH guideline suggested that RBC for antibody detection need to possess the following 
antigens: C, D, E, c, e, K, k, Fya, Fyb, Jka, Jkb, S, s, M, N, P1, Lea and Leb and for 
maximum sensitivity in antibody detection, it is generally agreed that homozygosity for C, 
D, E, c, e, Fya, and Jka is preferable. There is no need for low-frequency antigens to be 
present for antibody detection (BCSH, 1996b, Garratty, 2002). 
 
 2.3.3  Microcolumn gel agglutination system  
 
The microcolumn gel technique was used in this study for ABO and RhD grouping, RBC 
antibody screening and identification and DCT. IAT performed in microcolumn gel 
agglutination systems is superior to the conventional tube LISS-IAT in the detection of 
alloantibodies of potential clinical significance (Weisbach et al., 2006, Weisbach et al., 
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1999). When comparing of the performance of three microcolumn gel agglutination 
systems in the detection of RBC alloantibodies (DiaMed-ID, Ortho BioVue, and Sanofi-
Pasteur Scangel), the sensitivity of all microtube column  systems in the detection of 
clinically significant RBC alloantibodies was similar (Weisbach et al., 1999). Cid et al. 
(2006) also did a study to compare of three microcolumn gel agglutination systems, DG 
Gel, DiaMed-ID and Ortho BioVue for antibody screening and found that all three column 
agglutination systems work well showing a high estimated diagnostic accuracy. (Cid et al., 
2006).  
The microcolumn gel agglutination system was presented in at Congress of the 
International Society of Blood Transfusion (ISBT) in 1998. This system used the principle 
of controlled centrifugation of the RBC through a dextran-acrylamide in specially design 
microtube contains predispense gel, diluents, buffer and reagents if applicable (Lapierre et 
al., 1990). Measured serum or plasma was dispensed into reaction chamber of microtube. 
The gel particles are porous and perform molecular sieving based on the size of the RBC 
agglutinates present in the microtube during centrifugation. Any agglutinated RBC remain 
fixed on the surface or suspended in the gel. Unagglutinated RBC travels through the gel 
particles and form the pellet at the bottom after the centrifugation. The centrifugation of 
the tubes must be strictly controlled because the false positive reaction increase if 
centrifugation is too low or short while false negative reaction increase if centrifugation is 
too fast or long. The principle of gel column agglutination system is shown in Figure 2.2. 
 
 
